drugset / Trial / NCT01530529
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
RandomizedCrossoverOpen-labelBasic science
Summary
The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects. Two doses of the modified-release formulation and one dose of the immediate-release formulation will be evaluated under fasted conditions. One dose of the modified-release formulation will also be evaluated in the presence of food.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-05180999 | Small molecule | 30 mg | — |
| Subject | PF-05180999 | Small molecule | 120 mg | — |
Indications
No indication recorded.